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CASE REPORT
A COVID-19 pregnant patient 
with thrombotic thrombocytopenic purpura: 
a case report
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Abstract 
Background: Pregnancy seems to increase the risk of thrombotic thrombocytopenic purpura (TTP) relapses and 
make the TTP more severe in any of the pregnancy trimesters, or even during the postpartum period.
Case presentation: This study highlights details of treating a COVID-19 pregnant patient who survived. This 21-year 
addicted White woman was admitted at her 29th week and delivered a stillbirth. She was transferred to another hos-
pital after showing signs of TTP, which was caused by a viral infection.
Conclusion: This viral infection caused fever and dyspnea, and the patient was tested positive for COVID-19 infection. 
A chest computed tomography scan showed diffuse multiple bilateral consolidations and interlobar septal thicken-
ing. She stayed at the Intensive Care Unit for 20 days and treated with plasmapheresis. As far as we know, this is the 
first report of a TTP pregnant patient with COVID-19 infection.
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Introduction
Pregnancy seems to increase the risk of thrombotic 
thrombocytopenic purpura (TTP) relapses and make 
the TTP more severe in any pregnancy trimesters or 
even during the postpartum period [1]. TTP is diag‑
nosed when a patient has at least three of the following 
symptoms: thrombocytopenia, microangiopathic hemo‑
lytic anemia (MAHA), end‑organ damage (mostly renal 
insufficiency), neurologic phenomena (such as seizures, 
strokes), and fever. It is rare to see all the symptoms in 
a patient [2, 3]. TTP is usually triggered by bacterial or 
viral infections, autoimmune diseases such as lupus, and 
malignancy [4].
Acquired TTP presents as a severe MAHA and throm‑
bocytopenia in a healthy individual. In a patient with 
MAHA, who has a hemoglobin level lower than ten and 
the platelet level lower than 30,000, the patinaed will 
be diagnosed as a TTP patient. Lactate dehydrogenase 
(LDH) level and ADAMTS13 activity level can achieve 
the same result [5, 6]. Differential diagnoses in preg‑
nancy involve other conditions that contribute to having 
MAHA. These conditions include severe preeclampsia, 
HELLP syndrome, and disseminated intravascular coagu‑
lation (DIC) [7].
The most important therapy for TTP is doing plasma 
exchange to remove anti‑ADAMTS13 autoantibodies. 
Plasma exchange should be administrated to reach at 
least 150,000/mm3 of platelets for 3 successive days, and 
LDH level of at most 500 U/l [8]. Introducing this treat‑
ment was a big jump, which reduced the mortality rate 
of TTP to 20% compared to the previously reported 90% 
[9]. Glucocorticoid therapy is a second treatment for 
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TTP patients that can reduce the creation of the anti‑
ADAMTS13 autoantibody [10].
This study delves into finding how COVID‑19 affects 
the pregnancy outcome in a rare condition. It focuses on 
viral infections as one of the causes of TTP. We report a 
drug‑addicted TTP patient affected by COVID‑19, who 
just delivered her baby, and we discuss the postpartum 
conditions in detail. We are going to share our case to 
increase knowledge on how to treat TTP patients with 
such complicated conditions.
Case study
A 21 years old White woman with gravida 1 and para 1 
and intra uterine fetal death, who had a 29‑week gesta‑
tion, was admitted to RobatKarim Hospital, Tehran, 
Iran on March 20, 2020. The patient did not have a his‑
tory of hospitalization, and she did not report any health 
issues among her family members. She was a housewife 
from a middle‑class family who was living with his hus‑
band. Also, she was not a relative of her husband. She 
vaginally delivered a macerated male baby with 1300  g. 
As she stated, the pregnancy was unintended, and there 
was not any documented treatment found during the 
pregnancy months. The TTP patient who delivered her 
child and had a COVID‑19 infection. As she stated, she 
did not have any severe preeclampsia signs, such as head‑
aches and visual changes. She had fever, and sporadic 
dry coughs starting a week before the due date. She was 
tested positive for COVID 19.
She was a heavy smoker (did not take alcoholic bever‑
ages) and addicted to methamphetamine (for example, 
crystal) for a long time, and as she declared, she stopped 
taking methamphetamine during the last month before 
giving birth. She was treated with one loading dose of 
magnesium sulfate (4  g/IV (Intravenous)/stat), as well 
as antibiotics, such as ampicillin (2 g/IV/every 6 hours), 
Clindamycin (600 mg/IV/every 8 hours) and gentamicin 
(80 mg/IV/every 12 hours). Her condition deteriorated as 
the laboratory tests showed; the creatinine level became 
5.6 mg/dl, the platelet was decreased to 23,000/mm3 and 
hemoglobin was decreased to 8.9 g/dl.
On March 21, 2020, she was sent to Firoozgar teach‑
ing hospital, Tehran, Iran, which Iran University of 
Medical Sciences administrated. At the time of admis‑
sion, she was awake, conscious, and had a normal 
mental state. Her neurological examination, including 
cranial nerves, motor, sensory and cerebellar examina‑
tion, were within normal ranges. Her blood pressure 
and body temperature and respiratory rate and pulse 
rate were 125/80 mmHg, 38.4 ℃ (oral), 26/minute, and 
110/minute, respectively. Auscultation of both lungs 
and the heart showed fine crackles and tachycardia. 
Uterus was contracted, and we did not see any tender‑
ness in liver palpation in the abdominal examination, 
and extremities examination showed that she had pete‑
chia on the inner surface of the arms.
The electrocardiogram was normal and Chest X‑ray 
showed that both lungs had signs of diffused opacity. 
Chest computerized tomography (CT) showed signs of 
ground glass lung opacities (Fig.  1a), diffuse multiple 
bilateral consolidations (Fig.  1b), and diffuse bilateral 
fine interlobar septal thickening (Fig.  1c). As the lit‑
erature shows, these are evidence for having viral lung 
infection and positive COVID‑19 [11, 12].
Figure  2 shows peripheral blood smear anomalies, 
including anemia, thrombocytopenia, anisocytosis, 
poikilocytosis, macrocytosis and schistocytes.
Polymerase chain reaction (PCR) test obtained by 
nasopharyngeal swabs specimen confirmed that she 
was positive for COVID‑19. She did not have genetic 
testing for TTP. The viral infection tests, including 
Human Immunodeficiency Virus (HIV) antibody, Hep‑
atitis B Surface (HBS) antigen, anti‑HCV (Hepatitis C 
Virus) anti body were negative. The lupus blood test 
showed that anti double strand DNA, anti‑coagulant, 
and anti‑cardiolipin anti body were negative. The com‑
plement of C3 and C4 were in the normal range (C3 
was equal to 101 mg/dl, and C4 was equal to 19 mg/dl).
Table  1 provides the results of laboratory tests for 
5 days. As it shows for the second day, she had leukocy‑
tosis (Leukocyte was equal to 21,600 count/mm3), low 
hemoglobin level (4.9 g/dl), low platelets level (25,000/
mm3), high serum creatinine level (4.7 mg/dl), and high 
lactate dehydrogenase level (1050 U/l).
Her hemoglobin level dropped to 5.0  g/dl and we 
transfused the packed red blood cells. Hematologists 
suggested taking Dexamethasone at the rate of 8  mg/
day. She had premature membrane rupture along with 
malodor vaginal discharge and endometritis, so she 
took antibiotics, including Clindamycin in the rate of 
600  mg/IV/(every 8 hours), Meropenem at the rate of 
500  mg/(every 12  hours). It should be mentioned that 
the doses were adjusted to creatinine clearance. She 
also got dialysis treatment for 2 successive days as the 
serum creatinine level was raised.
Infectious disease specialists started to treat the 
patient with Kaletra (in one combined dosage of Lopi‑
navir in the rate of 100 mg and Ritonavir in the rate of 
400 mg) and Hydroxychloroquine 400 mg/stat followed 
by a continuous dose of it at the rate of 200 mg/ (every 
12 hours) for14 days.
Due to the presence of thrombocytopenia and an 
increase in LDH level to 1910  U/l, the hematologist 
treated her with plasmapheresis. The hematologist 
suggested exchanging 2.5  l of plasma with 2  l of fresh 
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frozen plasma for 5 consecutive days, which resulted in 
achieving platelet to 155,000 per cubic millimeter and 
lowering LDH level to 450 U/l.
Our multi‑disciplinary health team strived to save 
the patient, and finally the patient started to feel bet‑
ter as the body temperature returned to normal (i.e., 
break the fever). The patient did not have any signs 
of dyspnea on the 20th day of ICU hospitalization. 
Additionally, the leukocyte level returned to normal, 
and the kidney started to function healthily. She was 
in ICU for 24 days until March 27, 2020, and then 
she was transferred to the Gynecological ward. This 
patient was finally discharged after 8 days. The patient 
Fig. 1. Chest computerized tomography scan of the patient; a Ground glass lung opacities, b diffuse multiple bilateral consolidations, and c diffuse 
bilateral interlobar septal thickening
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is cured at the moment and does not show any TTP 
symptoms afterwards. Her hemoglobin is 11  g/dl, 
platelet is 220,000/mm3, LDH is 200  U/l, and creati‑
nine is 0.9 mg/dl.
Discussion
World Health Organization declared COVID 19 a global 
pandemic on March 11, 2020 [13]. COVID 19 can cause 
complicated situations for patients who have underly‑
ing medical conditions. A 21 years old drug‑addicted 
woman was admitted to a hospital. She was tested posi‑
tive for COVID 19 at the time of admission and delivered 
a stillbirth fetus. Then, she showed the early symptoms 
of TTP, including haemoglobin level of 5 g/dl, platelet of 
23,000/mm3, and creatinine level of 5.6 mg/dl, and schis‑
tocytes in the peripheral blood smear. She did not have 
any symptoms of TTP before hospitalization. And she 
showed the symptoms for the first time during her preg‑
nancy. Also, this patient had normal liver enzymes, and 
she did not have any severe preeclampsia symptoms. She 
responded to plasmapheresis and was cured. Moreover, 
at the moment, which is 6 months after her delivery, she 
does not have any TTP symptoms. By taking all these fac‑
tors into account, we believe that her TTP was acquired.
Literature found that pregnant women are going 
through some physiological changes that affect their 
immune systems. This affection may predispose such 
people to viral respiratory infections such as COVID‑19, 
a cause of TTP [14–16]. This study summarizes the chal‑
lenges that the medical team faced during this process 
in order to find how COVID‑19 affects the pregnancy 
outcome in a rare condition. As we are learning how 
COVID‑19 interferes with organs’ functions, we share 
the diagnosis and treatment steps for curing a TTP preg‑
nant woman as of the first study of its kind.
Karami et al., in March 2020, reported a 27 years preg‑
nant woman with COVID‑19 symptoms such as fever, 
myalgia, and cough, which are similar to our case. [17] 
Our case has leukocytosis, which could be a positive 
sign for her survival; however, the 27 years case suffered 
from leukopenia and lymphopenia. In both of the cases, 
Reverse Transcription Polymerase Chain Reaction con‑
firmed the presence of COVID‑19 infection. However, 
the results of the Chest CT scan at the time of hospitali‑
zation were different between these studies, as the CT of 
our patient was similar to the CT of COVID‑19 patients. 
Both cases started treatment for COVID 19, and both 
cases had a stillbirth. Literature listed Intrauterine fetal 
death as an outcome of infection with a family cluster 
of coronaviruses such as MERS (Middle Eastern Res‑
piratory Syndrome Coronavirus)‑COV and SARS(Severe 
Acute Respiratory Syndrome)‑COV [14–16, 18]. Since 
we admitted our patient to the ICU sooner, she survived, 
Fig. 2. Peripheral blood smear anomalies
Table 1 Laboratory results of the patient
AST Aspartate Aminotransferase; ALT Alanine Transaminase; PT Prothrombin 
Time; PTT Partial Thromboplastin Time; INR International Normalized Ratio; CPR 
Cardiopulmonary Resuscitation; N/A No information was collected
Hospitalization day Day 1 Day 2 Day 3 Day 4 Day5
Hemoglobin g/dl 5.0 4.9 6.1 7.9 8.1
Leukocyte count/mm3 11,000 21,600 29,000 28,800 18,600
Platelets /mm3 21,000 25,000 20,000 42,000 99,000
Fasting blood sugar mg/dl 98 87 85 87 100
Urea mg/dl 271 140 109 92 64
Creatinine mg/dl 5.6 4.7 2.3 1.3 1
Sodium mEq/l 134 143 137 142 138
Potassium mEq/l 5.7 4.7 3.6 3.4 4.2
AST u/l 24 30 33 31 36
ALT u/l 10 30 22 20 23
Bilirubin mg/dl 1.8 1.6 1.5 1.3 1.1
Albumin g/dl 2.3 3.2 3 3.5 3.7
Lactate dehydrogenase u/l 1,910 1,050 889 745 669
D-Dimer Negative N/A N/A N/A N/A
Serum bicarbonate mmol/l 15.1 19.3 18.8 17.3 22.0
Urine analysis (protein) Negative N/A N/A 1+ N/A
Urine analysis (blood) 2+ N/A N/A 3+ N/A
Fibrinogen mg/dl 403 N/A N/A N/A N/A
PT (seconds) 13.5 13 12.5 13.5 13
PTT (seconds) 24 33 25 30 28
INR 1 1.5 1.1 1.2 1.1
CRP (mg/ dl) 24 N/A N/A N/A 4
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while the 27 years patient died due to the multi‑organ 
failure.
Another study took nine pregnant women with ges‑
tational ages greater than or equal to 36 weeks with 
COVID‑19 infection, each of them had only one symp‑
tom from the typical symptoms [12] (i.e., fever, cough, 
myalgia, and dyspnea). Our patient was in her 29th week 
and had all of the common symptoms, and she survived 
while the patient died in this study. Each of the cases had 
a stillbirth, which can be explained in the case of infec‑
tion. In more severe cases with COVID‑19 infection, 
the virus may cause pneumonia that reduces the lungs’ 
capacity. This reduction in the capacity develops hypoxia 
in a pregnant patient that stops oxygen delivery to the 
fetus [15]. This causes Intrauterine Fetal Death (IUFD), 
which was happened in our case. We have a rich litera‑
ture discuss the effect of influenza and other known res‑
piratory infections in pregnancy [14], which happened to 
be similar in our patient who had COVID‑19.
Another study considered 13 pregnant women with 
COVID‑19; 10 cases undergone cesarean section due 
to the complicated conditions, such as fetal distress and 
premature rupture of the membrane (PROM) [15, 19]. 
Our case vaginally delivered a stillbirth, and the mother 
survived, while this study reports the death of one of the 
patients who had a stillbirth. This patient experienced 
multiple organ damages, including acute kidney injury, 
acute hepatic failure, and septic shock. Additionally, she 
went to ICU, and she was intubated due to the occur‑
rence of acute respiratory distress syndrome [19].
Other studies treated a pregnant TTP patient effec‑
tively with plasmapheresis and glucocorticoid [20]. The 
major difference between this study and ours is that this 
study knew that the patient had TTP who finally suffered 
a relapse, while our patient was not previously treated for 
TTP. In our case, we believe that COVID‑19, as a viral 
infection, stimulated anti‑ADAMTS13 autoantibodies.
Another study treated a pregnant TTP patient who only 
had HELLP syndrome without COVID‑19 infection [21]. 
The blood pressure of our case was normal, which ruled 
out the presence of HELLP syndrome. In both cases, 
high LDH, anemia, and thrombocytopenia confirm that 
the patients had MAHA, which is one of the hallmarks 
of TTP. In our case, Fig. 2 confirms this information as it 
visualizes fragmented erythrocytes in the shape of tear‑
drops. To treat the TTP, our patient took Hydrocortisone 
100 mg/IV/stat and then Dexamethasone 4 mg/IV/(every 
8 hours) as well as having plasmapheresis daily for 5 days. 
It should be noted that we applied this treatment due to 
the severe condition of our patient, as even measuring 
the ADAMTS13 activities could not be suggested as a 
reliable diagnostic test at the acute phase [21].
Conclusion
To summarize our case, pregnancy and the presence of 
the viral infection could be the triggers of TTP [6, 22, 23], 
which causes a critical risk for both mother and the child 
[24]. Literature shows that infections such as influenza, 
SARS‑COV, and MERS‑COV could increase the risk of 
maternal mortality, spontaneous miscarriage, preterm 
labor, and intrauterine growth restriction during preg‑
nancy [15, 25]. In our case, we believe that the COVID‑
19 behaves similarly to other viral infections. Thus, we 
can consider TTP or COVID‑19 as different etiologies 
engender the IUFD. It should be mentioned that COVID‑
19 does not have a proven treatment. Frontline workers 
are treating patients with potential therapy, such as anti‑
viral drugs and immunotherapies. We believe that if our 
patient was hospitalized sooner, she could have saved the 
baby, as the medical procedure we followed to save this 
TTP patient could benefit the baby as well. We recom‑
mend to other colleagues to consider this approach while 
they admit a pregnant patient.
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